Is a pan-European approach the way forward for health technology assessment?
This article was originally published in Clinica
Health technology assessment (HTA) and its increased influence on healthcare payers' decision-making process has a potentially profound impact on medtech manufacturers. In this article, Dr Mark Charny of UK consultancy Translucency examines the different components of HTA in Europe and whether a pan-EU HTA system is viable, as well as the growing importance of evidence-based medicine to help define the most effective clinical care
You may also be interested in...
In the final part of Clinica’s series on heath technology assessment in the EU, Mark Charny looks beyond HTA and discusses what factors to consider when gauging the reimbursement potential of your product from a payer’s perspective
In the second part of Clinica’s new series on health technology assessment in the EU, Mark Charny discusses how medtech companies can plan their HTA strategy on a country-specific level and on a broader EU level
Mark Charny provides an update on the key initiatives that have been rolled out in the EU to support cross-border collaboration on health technology assessment for medical devices.